Skip to main content
SpringerLink
Log in

Apixaban cost effective for stroke prevention in Greece

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Athanasakis K, et al. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. American Journal of Cardiovascular Drugs : 23 Nov 2016. Available from: URL: http://doi.org/10.1007/s40256-016-0204-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apixaban cost effective for stroke prevention in Greece. PharmacoEcon Outcomes News 768, 10 (2016). https://doi.org/10.1007/s40274-016-3608-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3608-x

Search

Navigation